Publications by authors named "Yo Matsuo"

Claim this Profile
C
Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Suyoun Chung, Kyoko Kijima, Aiko Kudo, Yoshiko Fujisawa, Yosuke Harada, Yo Matsuo

Oncotarget· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX.
Theodore Vougiouklakis, Vassiliki Saloura, Jae-Hyun Park, Naofumi Takamatsu, Takashi Miyamoto, Yo Matsuo

Oncotarget· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling.
Xiaolan Deng, Ryuji Hamamoto, Theodore Vougiouklakis, Rui Wang, Yuichiro Yoshioka, Yo Matsuo

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yuichiro Yoshioka, Takehiro Suzuki, Yo Matsuo, Giichiro Tsurita, Toshiaki Watanabe

Cancer Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Jae-Hyun Park, Hiroyuki Inoue, Taigo Kato, Makda Zewde, Takashi Miyamoto, Yo Matsuo

Cancer Sci· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of small molecular compounds targeting cancer stem cells.
Jae-Hyun Park, Suyoun Chung, Yo Matsuo, Yusuke Nakamura

Medchemcomm· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
Vassiliki Saloura, Theodore Vougiouklakis, Makda Zewde, Xiaolan Deng, Kazuma Kiyotani, Yo Matsuo

Sci Rep· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
Yuichiro Yoshioka, Takehiro Suzuki, Yo Matsuo, Makoto Nakakido, Giichiro Tsurita

Oncotarget· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Suyoun Chung, Kyoko Kijima, Aiko Kudo, Yoshiko Fujisawa, Yosuke Harada, Yo Matsuo

Oncotarget· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Taigo Kato, Hiroyuki Inoue, Seiya Imoto, Yoshinori Tamada, Takashi Miyamoto, Yo Matsuo

Oncotarget· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Hiroyuki Inoue, Taigo Kato, Sope Olugbile, Kenji Tamura, Suyoun Chung, Yo Matsuo

Oncotarget· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Houda Alachkar, Martin Mutonga, Gregory Malnassy, Jae-Hyun Park, Noreen Fulton, Yo Matsuo

Oncotarget· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Houda Alachkar, Martin B G Mutonga, Klaus H Metzeler, Noreen Fulton, Gregory Malnassy, Yo Matsuo

Oncotarget· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.
Yo Matsuo, Jae-Hyun Park, Takashi Miyamoto, Shinji Yamamoto, Shoji Hisada

Sci Transl Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Suyoun Chung, Hanae Suzuki, Takashi Miyamoto, Naofumi Takamatsu, Ayako Tatsuguchi, Yo Matsuo

Oncotarget· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In silico functional profiling of small molecules and its applications.
Tomohiro Sato, Yo Matsuo, Teruki Honma, Shigeyuki Yokoyama

J Med Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid oligomer conformation in a group of natively folded proteins.
Yuji Yoshiike, Ryoichi Minai, Yo Matsuo, Yun-Ru Chen, Tetsuya Kimura

PLoS One· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Method for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions.
Ryoichi Minai, Yo Matsuo, Hiroyuki Onuki, Hiroshi Hirota

Proteins· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study on the structure and cytopathogenic activity of HIV Vpr/Vpx proteins.
Boonruang Khamsri, Fumiko Murao, Akiko Yoshida, Akiko Sakurai, Tsuneo Uchiyama, Yo Matsuo

Microbes Infect· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the interaction between interleukin-13 and interleukin-13 receptors.
Kazuhiko Arima, Kazuo Sato, Go Tanaka, Sachiko Kanaji, Tohru Terada, Yo Matsuo

J Biol Chem· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma.
Kohei Saito, Takanori Kigawa, Seizo Koshiba, Kazuo Sato, Yo Matsuo

Structure· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16).
Takeshi Maeda, Makoto Inoue, Seizo Koshiba, Takashi Yabuki, Masaaki Aoki, Yo Matsuo

J Biol Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The squamous cell carcinoma antigen 2 inhibits the cysteine proteinase activity of a major mite allergen, Der p 1.
Yasuhisa Sakata, Kazuhiko Arima, Toshiro Takai, Wataru Sakurai, Kiyonari Masumoto, Yo Matsuo

J Biol Chem· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solution structure of a BolA-like protein from Mus musculus.
Takuma Kasai, Makoto Inoue, Seizo Koshiba, Takashi Yabuki, Masaaki Aoki, Yo Matsuo

Protein Sci· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pin1 and Par14 peptidyl prolyl isomerase inhibitors block cell proliferation.
Takafumi Uchida, Mari Takamiya, Morito Takahashi, Hitoshi Miyashita, Hisafumi Ikeda, Yo Matsuo

Chem Biol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis